-transparent.png){kind=logo}
1 The pharmacokinetics of two different sustained-release oral procainamide preparations were studied in ten hospital patients with normal blood ureas and no clinical evidence of heart failure. Each patient received either one or other preparation at 12 hourly intervals for four doses. Frequent blood sampling enabled close monitoring of blood levels. 2 Results showed that both preparations were essentially similar in their pharmacokinetics. Both effectively double the half-life of conventional oral procainamide to 6.5 h and are suitable as prophylactic preparations. One patient developed toxic levels, thought to be related to her metabolic status of being a very slow acetylator. To avoid toxicity pre-therapy assessment of a patient's cardiac and renal function and acetylator status is advised.
P Hore, and
P Bones, and
T Rollinson, and
H Ikram
May 1983,
American journal of diseases of children (1960),
P Hore, and
P Bones, and
T Rollinson, and
H Ikram
February 1988,
Clinical pharmacy,
P Hore, and
P Bones, and
T Rollinson, and
H Ikram
June 1985,
American heart journal,
P Hore, and
P Bones, and
T Rollinson, and
H Ikram
November 1975,
Current therapeutic research, clinical and experimental,
P Hore, and
P Bones, and
T Rollinson, and
H Ikram
January 1984,
The Journal of asthma : official journal of the Association for the Care of Asthma,
P Hore, and
P Bones, and
T Rollinson, and
H Ikram
January 1976,
Pharmaceutica acta Helvetiae,
P Hore, and
P Bones, and
T Rollinson, and
H Ikram
June 1984,
Drug intelligence & clinical pharmacy,
P Hore, and
P Bones, and
T Rollinson, and
H Ikram
February 1982,
Angiology,
P Hore, and
P Bones, and
T Rollinson, and
H Ikram
April 1985,
Archives of internal medicine,
P Hore, and
P Bones, and
T Rollinson, and
H Ikram
September 1984,
Annals of internal medicine,
